Astrazeneca (AZN) Assets Average (2009 - 2026)

Astrazeneca (AZN) has reported Assets Average for 18 consecutive years, with $114.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average rose 8.47% year-over-year to $114.0 billion; the TTM figure through Mar 2026 stood at $114.0 billion (up 8.47% YoY), while the FY2025 annual figure was $109.1 billion, up 109.02% from the prior year.
• Assets Average came in at $114.0 billion for Q1 2026 at Astrazeneca, roughly flat from $114.3 billion in the prior quarter.
• The five-year high for Assets Average was $114.3 billion in Q4 2025, with the low at $48.2 billion in Q4 2023.
• Average Assets Average over 5 years is $93.9 billion, with a median of $98.4 billion recorded in 2022.
• Across the five-year window, Assets Average sank 49.44% in 2023 and soared 116.76% in 2024, its largest moves.
• Year by year, Assets Average stood at $95.3 billion in 2022, then tumbled by 49.44% to $48.2 billion in 2023, then soared by 116.76% to $104.5 billion in 2024, then gained by 9.37% to $114.3 billion in 2025, then retreated by 0.19% to $114.0 billion in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $114.0 billion, $114.3 billion, and $113.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.